Albumin-bound paclitaxel in treatment of esophageal cancer

Objective To observe the curative effect of albumin-bound paclitaxel on esophageal cancer and its adverse reactions. Methods Fourteen patients with esophageal cancer admitted to our hospital from January 2009 to June 2011 were retrospectively analyzed.The patients were treated with intravenous albumin-bound paclitaxel at the dose of 100-260mg/m2,once every 3 weeks,at least for 4 cycles.The curative effect was assessed every two cycles. Results Among the 14 patients,complete remission（CR）,partial remission（PR）,stability and improvement of the disease were achieved in 1,7,5 and 1 patients,respectively,with no severe allergic reaction occurred in any patient.The main adverse reactions were neurotoxicity and neutropenia. Conclusion Albumin-bound paclitaxel is better in safety,shorter in infusion time,and broader in clinical application than polyethylated castor oil-based paclitaxel.